CONFERENCE UPDATES: ESMO 2021
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab shows efficacy for early-stage TNBC: KEYNOTE-522 phase 3 trial
04 Oct 2021
Related Articles
CONFERENCE UPDATES: ESMO 2021
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab shows efficacy for early-stage TNBC: KEYNOTE-522 phase 3 trial